Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis

International Journal of Clinical Practice

Volumn 55, Issue 8, 2001, Pages 505-509

  Dursun, N ^a,b   Dursun, E ^a,b   Yalcin S ^a,b  

^a University Faculty of Medicine   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; SALCATONIN;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; PAIN; PAIN ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK; SIDE EFFECT; STATISTICAL ANALYSIS; VERTEBRA FRACTURE;

ALENDRONATE; ANALYSIS OF VARIANCE; BONE DENSITY; CALCITONIN; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN; QUALITY OF LIFE;

EID: 0034760774     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Santoro NF, Col NF. Eckman MH el al. Therapeutic controversy: hormone replacement therapy - where are we going? J Clin Endocrinol Metab 1999; 84: 1789-1812.
2. Downs RW. Bell NH. Ettinger MP el ai. Comparison of alendronate and intranasal ealeitonin of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000: 85(5): 1783-1788.
3. Adami S, Passeri M, Ortolani S et al. Effects of oral alendronate and intranasal salmon ealeitonin on bone mass bioehemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383-390.
4. Lindsay R. Johnston CC. Physician's guide to prevention und treatment ofosieopurosia. New Jersey: Excerptu Medica. 1999.
5. Uarnero P, Shin WJ.Gineyts E et al. Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994: 79: 1693-1700.
6. Liberman UA. Weiss SR. Broil J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. ,V Eiif-1 J Med 1995: 333: 1437-1443.
7. Black DM. Cummings SR, Karpf DB el al. RandomiJ.ed trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
8. Pols HAP. Felsenberg D, Hanley DA et al. Multinational placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osleopor Int 1999; 9: 461-468.
9. Civitelli R.Gonnelli S.Zacchci F et al. Bone turnover in postmenopausal osteoporosis. J Clin Invest 1988; 82: 1268-1271.
10. Overgaard K, Hansen MA, Nelsen VAH et al. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990:89: 1-7.
11. Overgaard K, Hansen MA, Jensen BS et al. Effect of salcatonin given intranasally on bone mass, fracture rates in established osteoporosis: a dose response study. BMJ 1992; 305: 556-559.
12. Gennari C, Agnusdei D, Montagnani M et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50: 381-385.
13. Kanis JA. Johnell O, Gullberg B el al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992: 305: 1124-1126.
14. Rico H, Hernandez ER, Reveilla M et al. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992: 16: 131-137.
15. Chesnut CH III, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence Of Osteoporotic Fractures (PROOF) study. Am J Med 2000; 109: 267-276.
16. Dawson-Hughes B. Dallal GE, Krall EA et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990: 323: 878-883.
17. Devine A, Dick IM, Heal SJ et al. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporosis Int 1997; 7: 23-28.
18. Prelevic CM, Adashi EY. Postmenopausal osteoporosis: prevention and treatment with calcitonin. Gynecol Endocrinol 1992; 6: 141-147.
19. Yoshimura M. Analgesic mechanism of calcitonin. J Bone Miner Melah 2000; 18(4): 230-233.
20. Ito A, Kumamoto E, Takeda M et til. Mechanisms for ovariectomyinduced hyperalgesia and its relief by calcitonin: participation of 5-HT1Alike receptor on C-afferent terminals in substantiagelatinosa of the rat spinal cord. J Neurosci 2000: 20( 16): 6302-6308.
21. Lyritis GP. loannidis GV, Karachalios T et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15(4): 284-289.
22. Adami S, Fossaluzza V, Gatti D et al. Biphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997; 56(3): 201-204.
23. Newitt MC. Thompson DE, Black DM el al. Effect of alendronate on limited-activity days caused by back pain in postrnenopusal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160(1): 77-85.
24. Wisenski LA. Clinical management of postmenopausal osteoporosis. Southern Med J 1992; 85(8): 832-839.